202 related articles for article (PubMed ID: 10995904)
1. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival.
Bond G; Reyes J; Mazariegos G; Wu T; Schaefer N; Demetris J; Fung JJ; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1197-8. PubMed ID: 10995904
[No Abstract] [Full Text] [Related]
2. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
Pinna AD; Weppler D; Nery JR; Khan F; Ruiz P; Kato T; De Faria W; Berho M; Tzakis AG
Transplant Proc; 2000 Sep; 32(6):1193-4. PubMed ID: 10995902
[No Abstract] [Full Text] [Related]
3. The long-term efficacy of multivisceral transplantation.
Madariaga JR; Reyes J; Mazariegos G; Fung JJ; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1219-20. PubMed ID: 10995918
[No Abstract] [Full Text] [Related]
4. The efficacy of daclizumab for intestinal transplantation: preliminary report.
Abu-Elmagd K; Fung J; McGhee W; Martin D; Mazariegos G; Schaefer N; Demetris J; Starzl TE; Reyes J
Transplant Proc; 2000 Sep; 32(6):1195-6. PubMed ID: 10995903
[No Abstract] [Full Text] [Related]
5. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
[TBL] [Abstract][Full Text] [Related]
6. Experience with intestinal transplantation at the University of Miami.
Tzakis A; Webb M; Nery J; Rogers A; Koutouby R; Ruiz P; Karatzas T; Thompson J; Ricordi C
Transplant Proc; 1996 Oct; 28(5):2748-9. PubMed ID: 8908037
[No Abstract] [Full Text] [Related]
7. Intestinal transplantation at the University of Miami-five years of experience.
Pinna AD; Weppler D; Nery J; Ruiz P; Kato T; Khan F; Levi D; Nishida S; De Faria W; Berho M; Tzakis AG
Transplant Proc; 2000 Sep; 32(6):1226-7. PubMed ID: 10995922
[No Abstract] [Full Text] [Related]
8. Isolated intestinal versus composite visceral allografts: causes of graft failure.
de Vera ME; Reyes J; Demetris J; Mazariegos G; Schaefer N; Vargas H; Bond G; Wu T; Fung J; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1221-2. PubMed ID: 10995919
[No Abstract] [Full Text] [Related]
9. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
Lácha J; Símová M; Nosková L; Teplan V; Vítko S
Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
[No Abstract] [Full Text] [Related]
10. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
11. Is severe rejection an indication for retransplantation?
Kato T; Berho M; Weppler D; Ruiz P; Pinna AD; Khan FA; Nery JR; Tzakis AG
Transplant Proc; 2000 Sep; 32(6):1201. PubMed ID: 10995907
[No Abstract] [Full Text] [Related]
12. Can antibody prophylaxis allow sparing of other immunosuppressives?
Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
[No Abstract] [Full Text] [Related]
13. Positive lymphocytotoxic crossmatch does not adversely affect survival in living donor liver transplantation.
Sugawara Y; Tamura S; Kaneko J; Togashi J; Makuuchi M; Kokudo N
Dig Surg; 2009 Feb; 26(6):482-6. PubMed ID: 20068321
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of intestinal transplantation at the University of Miami.
Misiakos EP; Weppler D; Bakonyi A; Nery JR; Pinna AD; Kato T; Rodriguez M; Ruiz P; Thompson J; Ricordi C; Tzakis AG
Transplant Proc; 1999; 31(1-2):569-71. PubMed ID: 10083240
[No Abstract] [Full Text] [Related]
15. Intestinal transplantation: 4-year experience.
Todo S; Tzakis A; Reyes J; Abu-Elmagd K; Furukawa H; Fung J; Starzl TE
Transplant Proc; 1995 Feb; 27(1):1355-6. PubMed ID: 7878909
[No Abstract] [Full Text] [Related]
16. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
[TBL] [Abstract][Full Text] [Related]
17. A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection.
Behrend M; Lück R; Köthe P; Pichlmayr R
Transplant Proc; 1996 Dec; 28(6):3110-1. PubMed ID: 8962205
[No Abstract] [Full Text] [Related]
18. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
[No Abstract] [Full Text] [Related]
19. Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graft.
Aoki T; Sugawara Y; Takahashi M; Kawaguchi Y; Kaneko J; Yamashiki N; Tamura S; Hasegawa K; Takahashi K; Kokudo N
J Gastroenterol; 2012 Apr; 47(4):486-8. PubMed ID: 22328021
[TBL] [Abstract][Full Text] [Related]
20. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.
Neumann UP; Lang M; Moldenhauer A; Langrehr JM; Glanemann M; Kahl A; Frei U; Bechstein WO; Neuhaus P
Transplantation; 2001 Apr; 71(8):1163-8. PubMed ID: 11374419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
